Trial Profile
MONARCH 2: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONARCH 2
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 05 Dec 2023 Results presented in an Eli Lilly and Company Media Release.
- 03 Nov 2023 Planned End Date changed from 30 Jan 2024 to 30 Dec 2024.
- 18 May 2023 This trial has been completed in Germany.